Entrada Therapeutics, Inc. (TRDA)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Entrada Therapeutics, Inc. (“Entrada” or the “Company”) (NASDAQ: TRDA). Investors who purchased Entrada securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/trda.
The investigation concerns whether Entrada violated federal securities laws.
After the market closed on December 19, 2022, Entrada issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) placed a clinical hold on the Company’s Investigational New Drug Application for ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy. The FDA indicated that they would provide an official Clinical Hold letter to Entrada within 30 days. On this news, Entrada’s stock price fell $3.93 per share, or 19.76%, to close at $15.96 per share on December 20, 2022.
If you are aware of any facts relating to this investigation or purchased Entrada securities, you can assist with this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.